Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China

作者：Anwen Xiong, Lei Wang, Jianhua Chen, Lin Wu, Baogang Liu, Jun Yao, Hua Zhong, Jie Li, Ying Cheng, Yulan Sun, Hui Ge, Ji‐Fang Yao, Qin Shi, Ming Zhou, Bolin Chen, Zhengxiang Han, Jinliang Wang, Qing Bu, Yanqiu Zhao, Junqiang Chen, Ligong Nie, Gaofeng Li, Xingya Li, Xinmin Yu, Yinghua Ji, Daqiang Sun, Xiaohong Ai, Qian Chu, Lin Yu, Hao Jiqing, Dingzhi Huang, Chengzhi Zhou, Chengzhi Zhou, Jinlu Shan, Hongzhong Yang, Xuewen Liu, Jing Wang, Yanhong Shang, Xiaodong Mei, Jie Yang, Mingxiu Hu, Mingxiu Hu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Caicun Zhou, Caicun Zhou · 发表于：The Lancet · 年份：2025 · DOI：10.1016/s0140-6736(24)02722-3 · 被引用次数：165 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Treatments and Mutations、Peptidase Inhibition and Analysis